Phase II Study of ZD1839 (Iressa), Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor in Patients With Advanced, Recurrent or Metastatic Salivary Gland Cancer (IRUSIRES0198).
Phase of Trial: Phase II
Latest Information Update: 26 Nov 2017
At a glance
- Drugs Gefitinib (Primary)
- Indications Salivary gland cancer
- Focus Therapeutic Use
- 22 Sep 2016 Status changed from active, no longer recruiting to completed.
- 18 May 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2017, as reported by ClinicalTrials.gov.
- 18 May 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov